Progress in Precision Medicine for Head and Neck Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Nov 9

PMID 39518152

Authors

Sanaz Vakili

Amir Barzegar Behrooz

Rachel Whichelo

Alexandra Fernandes

Abdul-Hamid Emwas

Mariusz Jaremko

Jaroslaw Markowski

Marek J Los

Saeid Ghavami

Rui Vitorino

Affiliations

Soon will be listed here.

Abstract

This paper presents a comprehensive comparative analysis of biomarkers for head and neck cancer (HNC), a prevalent but molecularly diverse malignancy. We detail the roles of key proteins and genes in tumourigenesis and progression, emphasizing their diagnostic, prognostic, and therapeutic relevance. Our bioinformatic validation reveals crucial genes such as AURKA, HMGA2, MMP1, PLAU, and SERPINE1, along with microRNAs (miRNA), linked to HNC progression. OncomiRs, including hsa-miR-21-5p, hsa-miR-31-5p, hsa-miR-221-3p, hsa-miR-222-3p, hsa-miR-196a-5p, and hsa-miR-200c-3p, drive tumourigenesis, while tumour-suppressive miRNAs like hsa-miR-375 and hsa-miR-145-5p inhibit it. Notably, hsa-miR-155-3p correlates with survival outcomes in addition to the genes RAI14, S1PR5, OSBPL10, and METTL6, highlighting its prognostic potential. Future directions should focus on leveraging precision medicine, novel therapeutics, and AI integration to advance personalized treatment strategies to optimize patient outcomes in HNC care.

References

Gonzalez-Avila G, Sommer B, Mendoza-Posada D, Ramos C, Garcia-Hernandez A, Falfan-Valencia R . Matrix metalloproteinases participation in the metastatic process and their diagnostic and therapeutic applications in cancer. Crit Rev Oncol Hematol. 2019; 137:57-83. DOI: 10.1016/j.critrevonc.2019.02.010. View

Sheng S, Su W, Mao D, Li C, Hu X, Deng W . MicroRNA-21 induces cisplatin resistance in head and neck squamous cell carcinoma. PLoS One. 2022; 17(4):e0267017. PMC: 9009694. DOI: 10.1371/journal.pone.0267017. View

Sharma P, Gupta A . MicroRNAs: potential biomarkers for diagnosis and prognosis of different cancers. Transl Cancer Res. 2022; 9(9):5798-5818. PMC: 8798648. DOI: 10.21037/tcr-20-1294. View

Halder S, Basu S, Lall S, Ganti A, Batra S, Seshacharyulu P . Targeting the EGFR signaling pathway in cancer therapy: What's new in 2023?. Expert Opin Ther Targets. 2023; 27(4-5):305-324. PMC: 10330690. DOI: 10.1080/14728222.2023.2218613. View

Kumarasamy C, Royam Madhav M, Sabarimurugan S, Krishnan S, Baxi S, Gupta A . Prognostic Value of miRNAs in Head and Neck Cancers: A Comprehensive Systematic and Meta-Analysis. Cells. 2019; 8(8). PMC: 6721479. DOI: 10.3390/cells8080772. View

Kajiyama T, Serada S, Fujimoto M, Ohkawara T, Komori M, Hyodo M . SOCS1 Gene Therapy for Head and Neck Cancers: An Experimental Study. Anticancer Res. 2022; 42(7):3361-3372. DOI: 10.21873/anticanres.15823. View

Mendez-Huergo S, Blidner A, Rabinovich G . Galectins: emerging regulatory checkpoints linking tumor immunity and angiogenesis. Curr Opin Immunol. 2017; 45:8-15. DOI: 10.1016/j.coi.2016.12.003. View

Nisa L, Barras D, Medova M, Aebersold D, Medo M, Poliakova M . Comprehensive Genomic Profiling of Patient-matched Head and Neck Cancer Cells: A Preclinical Pipeline for Metastatic and Recurrent Disease. Mol Cancer Res. 2018; 16(12):1912-1926. DOI: 10.1158/1541-7786.MCR-18-0056. View

Malumbres M . miRNAs and cancer: an epigenetics view. Mol Aspects Med. 2012; 34(4):863-74. PMC: 5791883. DOI: 10.1016/j.mam.2012.06.005. View

10.

Thomaidou A, Batsaki P, Adamaki M, Goulielmaki M, Baxevanis C, Zoumpourlis V . Promising Biomarkers in Head and Neck Cancer: The Most Clinically Important miRNAs. Int J Mol Sci. 2022; 23(15). PMC: 9367895. DOI: 10.3390/ijms23158257. View

11.

Khan A, Ahmed E, Elareer N, Junejo K, Steinhoff M, Uddin S . Role of miRNA-Regulated Cancer Stem Cells in the Pathogenesis of Human Malignancies. Cells. 2019; 8(8). PMC: 6721829. DOI: 10.3390/cells8080840. View

12.

Okano L, da Fonseca L, Erthal I, Malta T . Epigenomic integrative analysis pinpoint master regulator transcription factors associated with tumorigenesis in squamous cell carcinoma of oral tongue. Genet Mol Biol. 2023; 46(2):e20220358. PMC: 10280803. DOI: 10.1590/1678-4685-GMB-2022-0358. View

13.

Laprovitera N, Riefolo M, Porcellini E, Durante G, Garajova I, Vasuri F . MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primary. Mol Oncol. 2021; 15(10):2732-2751. PMC: 8486570. DOI: 10.1002/1878-0261.13026. View

14.

Solomon B, Young R, Rischin D . Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments. Semin Cancer Biol. 2018; 52(Pt 2):228-240. DOI: 10.1016/j.semcancer.2018.01.008. View

15.

Das T, Zhong R, Spiotto M . Notch Signaling and Human Papillomavirus-Associated Oral Tumorigenesis. Adv Exp Med Biol. 2020; 1287:105-122. PMC: 7751007. DOI: 10.1007/978-3-030-55031-8_8. View

16.

Lozano R, Castro E, Aragon I, Cendon Y, Cattrini C, Lopez-Casas P . Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer. Br J Cancer. 2020; 124(3):552-563. PMC: 7851123. DOI: 10.1038/s41416-020-01114-x. View

17.

Mody M, Rocco J, Yom S, Haddad R, Saba N . Head and neck cancer. Lancet. 2021; 398(10318):2289-2299. DOI: 10.1016/S0140-6736(21)01550-6. View

18.

Rawla P . Epidemiology of Prostate Cancer. World J Oncol. 2019; 10(2):63-89. PMC: 6497009. DOI: 10.14740/wjon1191. View

19.

Kozlowska-Maslon J, Guglas K, Kolenda T, Lamperska K, Makalowska I . miRNA in head and neck squamous cell carcinomas: promising but still distant future of personalized oncology. Rep Pract Oncol Radiother. 2024; 28(5):681-697. PMC: 10764040. DOI: 10.5603/rpor.96666. View

20.

Liang Y, Guan C, Li K, Zheng G, Wang T, Zhang S . MMP25 Regulates Immune Infiltration Level and Survival Outcome in Head and Neck Cancer Patients. Front Oncol. 2020; 10:1088. PMC: 7405909. DOI: 10.3389/fonc.2020.01088. View